|Bid||1.33 x 4800|
|Ask||1.34 x 200|
|Day's range||1.33 - 1.42|
|52-week range||0.92 - 1.68|
|PE ratio (TTM)||N/A|
|Earnings date||6 Nov 2017 - 10 Nov 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||1.95|
ArQule, Inc. today announced dosing of the initial patients in a registrational trial with its FGFR inhibitor, derazantinib in FGFR2 fusion driven second-line intrahepatic Cholangiocarcinoma .
The Burlington, Massachusetts-based company said it had a loss of 9 cents per share. ArQule expects a full-year loss of 40 cents to 38 cents per share. The company's shares closed at $1.10. A year ago, ...
ArQule, Inc. today announced the closing of a private placement with institutional investors led by The Pontifax Group pursuant to which the Company raised gross proceeds of $9.5 million through the sale of approximately 8,370 shares of series A convertible preferred stock and warrants covering 2,260 shares of Series A Preferred .
ArQule, Inc. today announced that the U.S. Food and Drug Administration has granted Rare Pediatric Disease Designation to miransertib for the treatment of Proteus syndrome.
ArQule, Inc. today announced it will report financial results for the third quarter 2017 before the market opens on Thursday, November 9, 2017. The Company will hold a conference call and webcast on the same day at 9:00 a.m.
ArQule, Inc. today announced the closing of a private placement with certain institutional investors, with leading participation by BVF Partners L.P., pursuant to which the Company raised gross proceeds of approximately $15.7 million through the sale of 13,938,651 shares of common stock and 3,123,674 warrants.
ArQule, Inc. (Nasdaq: ARQL) today announced that preclinical data for ARQ 531 in diffuse large B-cell lymphoma (DLBCL) in vitro and in vivo tumor models was presented at EHA Congress in Madrid, Spain. ARQ 531 is an investigational, orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK). The presentation titled “ARQ 531, A Reversible BTK Inhibitor, Demonstrates Potent Anti-Tumor Activity in ABC-DLBCL and GCB-DLBCL” can be viewed at https://www.arqule.com/wp-content/uploads/ARQ531_EHA_2017.pdf.
ArQule, Inc. (Nasdaq: ARQL) today announced that preclinical data for ARQ 531 in diffuse large B-cell lymphoma (DLBCL) in vitro and in vivo tumor models will be presented on June 23, 2017 at EHA Congress in Madrid, Spain. A phase 1 trial with ARQ 531 in patients with B-cell malignancies refractory to other therapeutic options, including ibrutinib, is planned to commence by the third quarter of 2017. ARQ 531 is an investigational, orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK).
ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo today announced that the METIV-HCC phase 3 study of tivantinib in hepatocellular carcinoma (HCC) did not meet its primary endpoint of improving overall survival. METIV-HCC is a biomarker-selected, double-blind, placebo-controlled, randomized phase 3 study evaluating tivantinib (2:1) versus best supportive care in patients with MET-overexpressing, inoperable HCC intolerant to or previously-treated with systemic therapy. The primary endpoint of the study is overall survival.